Suven Life Sciences granted patents for neurodegenerative drug

Tags: Companies
Pharmaceutical firm Suven Life Sciences has been granted three product patents -- one each by South Korea, China and Canada -- for drug used in the treatment of neurodegenerative diseases.

Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.

In a BSE filing the company said it has been granted "one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

These patents are valid through 2029, 2029 and 2031, respectively, the company said in a BSE filing.

Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."

With these new patents, Suven has a total of 14 granted patents from South Korea, 14 from China and 16 from Canada, respectively.

EDITORIAL OF THE DAY

  • By banning the sale of BS-III vehicles, SC has ruled in favour of public health

    Automobiles, commercial vehicles and two-wheeler manufacturers have no alternative but to comply with the Supreme Court directive of not selling BS-II

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

Cut & Thrust: SRK’s ALPHABET SOUP

On Saturday, the Enforcement Directorate sent a show cause notice ...

Ananda Majumdar

Power of risk in politics

A counter na-rrative appears to be emerging in the ongoing ...

Zehra Naqvi

Success lies in learning to embrace failure

Among the thronging multitudes that offer you lessons on success, ...